COGT
Neutral signalScored 2026-09-01 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Cogent Biosciences, Inc.
- Nom
- Cogent Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.4B
- Employés
- 258
- PDG
- Andrew R. Robbins
- Site web
- https://www.cogentbio.com
- Marché
- AVBPIDYAINCYKURAMAZENRIX
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 45 510 titres (~1 688 079,68 $ US)
- Insiders
- Morris Arlene
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$118,663
Avg sell (VWAP, 90d window) $37.54 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$118,663 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-27
- Last synced
-
2026-09-02 21:34:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-27 | Morris Arlene | Sell · S · 10b5-1 | 3,161 | $37.54 | $118,663 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-01 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $119K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $119K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 14.23 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.235 | 5.322 | 7.094 | 9.869 | 13.037 | |
| Quick Ratio | 14.235 | 5.322 | 7.094 | 9.869 | 13.037 | |
| Solvency Ratio | -1.077 | -3.512 | -3.394 | -2.981 | -3.925 | |
| Cash Ratio | 4.879 | 1.762 | 1.395 | 5.210 | 12.864 | |
| Price To Earnings Ratio | -17.412 | -3.362 | -2.430 | -5.115 | -4.638 | |
| Price To Earnings Growth Ratio | 1.443 | 0.814 | -0.343 | -0.231 | 0.067 | |
| Forward Price To Earnings Growth Ratio | 1.443 | 0.814 | -0.343 | -0.231 | 0.067 | |
| Price To Earnings Diluted Ratio | -17.412 | -3.362 | -2.430 | -5.115 | -4.638 | |
| Price To Earnings Diluted Growth Ratio | 1.443 | 0.814 | -0.343 | -0.231 | 0.067 | |
| Price To Book Ratio | 8.985 | 3.362 | 1.817 | 2.655 | 1.552 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -21.496 | -4.135 | -2.994 | -5.411 | -5.494 | |
| Price To Operating Cash Flow Ratio | -21.623 | -4.146 | -3.049 | -5.724 | -5.655 | |
| Debt To Assets Ratio | 0.270 | 0.053 | 0.060 | 0.065 | 0.014 | |
| Debt To Equity Ratio | 0.398 | 0.068 | 0.073 | 0.077 | 0.015 | |
| Debt To Capital Ratio | 0.285 | 0.064 | 0.068 | 0.071 | 0.015 | |
| Long Term Debt To Capital Ratio | 0.272 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.473 | 1.279 | 1.216 | 1.176 | 1.084 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.135 | -3.730 | -4.025 | -4.419 | -3.441 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | 1.003 | 1.018 | 1.058 | 1.029 | |
| Debt Service Coverage Ratio | -69.702 | 0.000 | 0.000 | -32.683 | 0.000 | |
| Interest Coverage Ratio | -108.871 | 0.000 | 0.000 | -37.062 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -170.940 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.045 | -11.896 | -8.149 | -6.038 | -18.625 | |
| Capital Expenditure Coverage Ratio | -170.170 | -362.637 | -54.944 | -17.287 | -34.184 | |
| Dividend Paid And Capex Coverage Ratio | -170.170 | -362.637 | -54.944 | -17.287 | -34.184 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -17.616 | -3.105 | -2.298 | -4.286 | -1.647 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.235 | ▲8.913 | ▲4.324 |
| Quick Ratio | 14.235 | ▲8.913 | ▲4.324 |
| Solvency Ratio | -1.077 | ▲2.436 | ▲1.901 |
| Cash Ratio | 4.879 | ▲3.117 | ▼-0.343 |
| Price To Earnings Ratio | -17.412 | ▼-14.050 | ▼-10.820 |
| Price To Earnings Growth Ratio | 1.443 | ▲0.629 | ▲1.093 |
| Forward Price To Earnings Growth Ratio | 1.443 | ▲0.629 | ▲1.093 |
| Price To Earnings Diluted Ratio | -17.412 | ▼-14.050 | ▼-10.820 |
| Price To Earnings Diluted Growth Ratio | 1.443 | ▲0.629 | ▲1.093 |
| Price To Book Ratio | 8.985 | ▲5.623 | ▲5.311 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -21.496 | ▼-17.361 | ▼-13.590 |
| Price To Operating Cash Flow Ratio | -21.623 | ▼-17.476 | ▼-13.583 |
| Debt To Assets Ratio | 0.270 | ▲0.217 | ▲0.177 |
| Debt To Equity Ratio | 0.398 | ▲0.330 | ▲0.272 |
| Debt To Capital Ratio | 0.285 | ▲0.221 | ▲0.184 |
| Long Term Debt To Capital Ratio | 0.272 | ▲0.272 | ▲0.217 |
| Financial Leverage Ratio | 1.473 | ▲0.194 | ▲0.228 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.135 | ▼-0.405 | ▼-0.185 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▲0.003 | ▼-0.017 |
| Debt Service Coverage Ratio | -69.702 | ▼-69.702 | ▼-49.225 |
| Interest Coverage Ratio | -108.871 | ▼-108.871 | ▼-79.684 |
| Short Term Operating Cash Flow Coverage Ratio | -170.940 | ▼-170.940 | ▼-136.752 |
| Operating Cash Flow Coverage Ratio | -1.045 | ▲10.852 | ▲8.106 |
| Capital Expenditure Coverage Ratio | -170.170 | ▲192.467 | ▼-42.325 |
| Dividend Paid And Capex Coverage Ratio | -170.170 | ▲192.467 | ▼-42.325 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -17.616 | ▼-14.511 | ▼-11.825 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $5.72B | $861.6M | $468.4M | $679.0M | $332.3M | |
| Enterprise value | $5.66B | $780.9M | $434.0M | $558.8M | $115.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -21.40x | -3.76x | -2.83x | -4.71x | -1.97x | |
| EV / Free cash flow | -21.27x | -3.75x | -2.77x | -4.45x | -1.91x | |
| EV / EBITDA | -17.62x | -3.10x | -2.30x | -4.29x | -1.65x | |
| Net debt / EBITDA | 0.18x | 0.32x | 0.18x | 0.92x | 3.08x | |
| Current ratio | 14.23x | 5.32x | 7.09x | 9.87x | 13.04x | |
| Income quality | 0.80x | 0.81x | 0.80x | 0.85x | 0.81x | |
| Graham net-net | $4 | $2 | $3 | $4 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.9% | 100.0% | 100.0% | 102.9% | 100.0% | |
| Working capital | $846.4M | $240.8M | $232.6M | $238.1M | $205.6M | |
| Invested capital | $869.9M | $267.3M | $262.9M | $269.2M | $210.0M | |
| Return on assets | -35.1% | -78.0% | -61.4% | -46.6% | -31.1% | |
| Operating ROA | -52.7% | -86.1% | -67.8% | -55.5% | -31.3% | |
| Return on tangible assets | -35.1% | -78.0% | -61.4% | -46.6% | -31.1% | |
| Return on equity | -51.7% | -99.8% | -74.6% | -54.8% | -33.7% | |
| Return on invested capital | -38.1% | -100.8% | -75.2% | -53.7% | -34.8% | |
| Return on capital employed | -38.2% | -101.4% | -75.6% | -54.0% | -35.1% | |
| Earnings yield | -5.8% | -29.7% | -41.1% | -20.7% | -21.7% | |
| Free cash flow yield | -4.7% | -24.2% | -33.4% | -18.5% | -18.2% | |
| Capex / Op. cash flow | -0.6% | -0.3% | -1.8% | -5.8% | -2.9% | |
| Capex / Depreciation | 33.9% | 13.2% | 77.9% | 116.8% | 1169.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 751d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -751d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-27 Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three NDAs, with regulatory decisions expected between late 2026 and early 2027. COGT''s commercial infrastructure and $865.9M liquidity provide a runway through 2028, supporting launch and early commercialization activities.
- 2026-08-24 Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 266,584 shares of the technology company''s stock, valued at approximately $10,317,000. Deutsche Bank AG owned approximately 0.16%
- 2026-08-18 Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGT Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 44,600 shares of the technology company''s stock, valued at approximately $1,726,000. A number of other institutional
- 2026-08-13 Cogent Biosciences (COGT) May Find a Bottom Soon, Here''s Why You Should Buy the Stock Now Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 2026-08-10 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.
- 2026-06-30 Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patients
- 2026-06-14 Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results.
- 2026-06-12 Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
- 2026-06-12 Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –